Additional data to be published in an upcoming issue of Anti-Cancer Drugs
VANCOUVER, March 20 /CNW/ - Protox(TM) Therapeutics Inc. (TSX-V:PRX)
today announced that two peer-reviewed publications will feature Protox's PRX
302. The Journal of the National Cancer Institute ("JNCI") has published the
work conducted by Dr. Sam Denmeade and his team at Johns Hopkins University in
collaboration with Protox scientists. The paper describes the Company's
compound, PRX302, which is a prostate specific antigen (PSA) activated
pro-drug being developed for the treatment of prostate cancer and BPH.
"Having results of our PRX302 research program published in a prestigious
journal such as JNCI is a testament to the importance of advancing PRX302 for
prostate cancer and BPH," stated Dr. Fahar Merchant, President and CEO of
Protox. "The published results are consistent with the encouraging interim
data from the ongoing Phase I prostate cancer trial reported earlier this year
and supports the planned Phase I BPH clinical trial which we expect to
commence in Q2 of 2007."
The major advantage of using PRX302 as a therapeutic agent for prostatic
diseases is that it involves direct injection into the target tissue and
selective activation by PSA produced only by the target tissue. The paper,
entitled "A prostate-specific antigen-activated channel-forming toxin as
therapy for prostatic disease" (JNCI, Vol.99, Issue 5 pp, 376-385) found that:
PRX302 direct injection into the prostate did not cause any attributable
accumulation of PRX302 outside of the prostate gland; is not toxic to adjacent
non-PSA producing organs and tissues; and PRX302 has a selective mechanism of
action and favourable safety profile.
A second paper entitled, "Recombinant prostate-specific antigen
proaerolysin shows selective protease sensitivity and cell cytotoxicity" is to
appear in the upcoming issue of Anti-Cancer Drugs (ACD). The journal will
publish the work conducted by Dr Arthur Frankel and his team at the Cancer
Research Institute of Scott and White Memorial Hospital in collaboration with
scientists at Protox and Johns Hopkins University. Key findings include: human
prostate cancer cells are significantly more sensitive to PRX302 in the
presence of active PSA; PRX302 was totally resistant to thrombin, matrix
metalloprotease 7 (MMP-7), human kallikrein 1 (hk1) and human
kallikrein 2 (hk2) activation; and among the normal cells tested, the
PSA-producing prostate epithelial cells were the only normal cells that were
highly sensitive to PRX302.
Both publications demonstrated that the PSA-activated strategy for PRX302
has a number of inherent advantages as a therapeutic strategy for locally
recurrent prostate cancer and BPH.
Protox Therapeutics is a leader in advancing novel, targeted protein
toxin therapeutics for treatment of cancer and other proliferative diseases.
The company is actively developing two distinct but complementary platforms,
INxin(TM) and PORxin, and currently has three clinical programs in
development. A Phase IIa clinical trial into the use of PRX321 (INxin) for the
treatment of primary brain cancer has been completed and the drug has received
Fast Track Designation and Orphan Drug Status from the US FDA. In addition, a
Phase I trial has been completed for PRX321 to treat patients with renal cell
carcinoma and non-small cell lung cancer. Patient enrolment is underway for a
Phase I clinical study into the use of PRX302 (PORxin) to treat localized
prostate cancer. PRX302 has also been approved by Health Canada to commence a
Phase I clinical study for the treatment of benign prostatic hyperplasia.
NO REGULATORY AUTHORITY HAS APPROVED OR DISAPPROVED THE CONTENT OF THIS
RELEASE. THE TSX VENTURE EXCHANGE DOES NOT ACCEPT RESPONSIBILITY FOR THE
ADEQUACY OR ACCURACY OF THIS RELEASE.
Certain statements included in this press release may be considered
forward-looking. Such statements involve known and unknown risks,
uncertainties and other factors that may cause actual results, performance or
achievements to be materially different from those implied by such statements,
and therefore these statements should not be read as guarantees of future
performance or results. All forward-looking statements are based on Protox'
current beliefs as well as assumptions made by and information currently
available to Protox and relate to, among other things, anticipated financial
performance, business prospects, strategies, regulatory developments, market
acceptance and future commitments. Readers are cautioned not to place undue
reliance on these forward-looking statements, which speak only as of the date
of this press release. Due to risks and uncertainties, including the risks and
uncertainties identified by Protox in its public securities filings; actual
events may differ materially from current expectations. Protox disclaims any
intention or obligation to update or revise any forward-looking statements,
whether as a result of new information, future events or otherwise.
For further information:
For further information: James Beesley, Director, Investor Relations,
Protox Therapeutics, (604) 688-0199, firstname.lastname@example.org; Michael
Moore, Investor Relations, Equicom Group, (416) 815-0700 x 241,